Schizophrenia researchHumansSchizophreniaNortropanesMaleAdult
Long-term efficacy, safety, and tolerability of xanomeline and trospium chloride in schizophrenia: A 52-week, open-label trial (EMERGENT-5).
Inder Kaul, Amy Claxton, Soumya Chaturvedi, Tejendra Patel, Hsiuanlin Wu, Sharon Sawchak, Colin Sauder
Published: 202610.1016/j.schres.2025.12.015
Abstract
BACKGROUND: The M1/M4 muscarinic receptor agonist xanomeline combined with the peripherally restricted pan-muscarinic receptor antagonist trospium chloride is the first approved treatment for adults with schizophrenia with no direct D2 dopamine recep…
Preview only. Read the full abstract at the source